PUBLIC COMPANY
save$KPTIKaryopharm Therapeutics Inc.
$KPTINewton, MA, USupdated 3mo ago
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- phase2A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
- phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase3Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
- phase3Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
- —Karyopharm Expanded Access Program for Selinexor
- phase2A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- phase2Selinexor and Backbone Treatments of Multiple Myeloma Patients
🐶 Hiring Signal
News
- Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raftDebtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with A…biospace · 14d ago
- Karyopharm, deep in debt, to sell itself in bankruptcyThe parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.biopharma_dive · 14d ago
- Karyopharm plans to merge with Ayrmid, the company that tried buying bluebirdWith few options remaining, a commercial-stage blood cancer biotech will go through a bankruptcy process and plans to merge with another drugmaker in the blood disorder field. Karyopharm Therapeuti…endpoints · 14d ago
- Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned mergerIn an answer to Karyopharm's cash crisis, Irish biotech Ayrmid has agreed to make the first bid on the struggling biopharma's assets in a court supervised auction, teeing up a potential hematology…fiercebiotech · 15d ago
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useKaryopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…biopharma_dive · 2mo ago
- Karyopharm has a month left to salvage its cancer expansion plansA commercial-stage cancer drugmaker with a market cap about one-third the size of its projected 2026 revenues is on the brink of defaulting. Karyopharm Therapeutics said Thursday that it has until ...endpoints · 3mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that